Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 55

1.

The effect of walking on cardiorespiratory fitness in adults with knee osteoarthritis.

Larose J, King J, Brosseau L, Wells GA, Reid R, Maetzel A, Tugwell P, Huijbregts M, McCullough C, Loew L, Kenny GP.

Appl Physiol Nutr Metab. 2013 Aug;38(8):886-91. doi: 10.1139/apnm-2012-0487. Epub 2013 Mar 21.

PMID:
23855277
2.

Therapies for active rheumatoid arthritis after methotrexate failure.

O'Dell JR, Mikuls TR, Taylor TH, Ahluwalia V, Brophy M, Warren SR, Lew RA, Cannella AC, Kunkel G, Phibbs CS, Anis AH, Leatherman S, Keystone E; CSP 551 RACAT Investigators.

N Engl J Med. 2013 Jul 25;369(4):307-18. doi: 10.1056/NEJMoa1303006. Epub 2013 Jun 11.

3.

Abatacept or infliximab for patients with rheumatoid arthritis and inadequate response to methotrexate: an Italian trial-based and real-life cost-consequence analysis.

Benucci M, Stam WB, Gilloteau I, Sennfält K, Leclerc A, Maetzel A, Lucioni C.

Clin Exp Rheumatol. 2013 Jul-Aug;31(4):575-83. Epub 2013 May 27.

PMID:
23711100
4.

The implementation of a community-based aerobic walking program for mild to moderate knee osteoarthritis: a knowledge translation randomized controlled trial: part II: clinical outcomes.

Brosseau L, Wells GA, Kenny GP, Reid R, Maetzel A, Tugwell P, Huijbregts M, McCullough C, De Angelis G, Chen L.

BMC Public Health. 2012 Dec 12;12:1073. doi: 10.1186/1471-2458-12-1073.

5.

The implementation of a community-based aerobic walking program for mild to moderate knee osteoarthritis (OA): a knowledge translation (KT) randomized controlled trial (RCT): Part I: The Uptake of the Ottawa Panel clinical practice guidelines (CPGs).

Brosseau L, Wells GA, Kenny GP, Reid R, Maetzel A, Tugwell P, Huijbregts M, McCullough C, De Angelis G, Chen L.

BMC Public Health. 2012 Oct 13;12:871. doi: 10.1186/1471-2458-12-871.

6.

Ottawa panel evidence-based clinical practice guidelines for aerobic walking programs in the management of osteoarthritis.

Loew L, Brosseau L, Wells GA, Tugwell P, Kenny GP, Reid R, Maetzel A, Huijbregts M, McCullough C, De Angelis G, Coyle D; Ottawa Panel.

Arch Phys Med Rehabil. 2012 Jul;93(7):1269-85. doi: 10.1016/j.apmr.2012.01.024. Epub 2012 Mar 12. Review.

PMID:
22421624
7.

Is a mass immunization program for pandemic (H1N1) 2009 good value for money? Evidence from the Canadian Experience.

Sander B, Bauch CT, Fisman D, Fowler RA, Kwong JC, Maetzel A, McGeer A, Raboud J, Scales DC, Gojovic MZ, Krahn M.

Vaccine. 2010 Aug 31;28(38):6210-20. doi: 10.1016/j.vaccine.2010.07.010. Epub 2010 Jul 17.

PMID:
20643091
8.

Economic appraisal of Ontario's Universal Influenza Immunization Program: a cost-utility analysis.

Sander B, Kwong JC, Bauch CT, Maetzel A, McGeer A, Raboud JM, Krahn M.

PLoS Med. 2010 Apr 6;7(4):e1000256. doi: 10.1371/journal.pmed.1000256.

9.

The OMERACT Initiative. Towards a reference approach to derive QALY for economic evaluations in rheumatology.

Boonen A, Maetzel A, Drummond M, Suarez-Almazor M, Harrison M, Welch V, Tugwell PS.

J Rheumatol. 2009 Sep;36(9):2045-9. doi: 10.3899/jrheum.090355.

PMID:
19738211
10.

A coordinator program in post-fracture osteoporosis management improves outcomes and saves costs.

Sander B, Elliot-Gibson V, Beaton DE, Bogoch ER, Maetzel A.

J Bone Joint Surg Am. 2008 Jun;90(6):1197-205. doi: 10.2106/JBJS.G.00980.

PMID:
18519311
11.

Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept.

Boonen A, Patel V, Traina S, Chiou CF, Maetzel A, Tsuji W.

J Rheumatol. 2008 Apr;35(4):662-7. Epub 2008 Feb 15.

PMID:
18278836
12.

Direct costs of osteoporosis and hip fracture: an analysis for the Mexican healthcare system.

Clark P, Carlos F, Barrera C, Guzman J, Maetzel A, Lavielle P, Ramirez E, Robinson V, Rodriguez-Cabrera R, Tamayo J, Tugwell P.

Osteoporos Int. 2008 Mar;19(3):269-76. Epub 2007 Dec 5.

PMID:
18060586
13.

Considerations and preliminary proposals for defining a reference case for economic evaluations in ankylosing spondylitis.

Bansback N, Maetzel A, Drummond M, Anis A, Marra C, Conway P, Boers M, Tugwell P, Boonen A.

J Rheumatol. 2007 May;34(5):1178-83.

PMID:
17477483
14.

Cost effectiveness analysis of disease modifying antirheumatic drugs in rheumatoid arthritis.

Osiri M, Kamolratanakul P, Maetzel A, Tugwell P.

Rheumatol Int. 2007 Sep;27(11):1063-9. Epub 2007 Apr 14.

PMID:
17440729
15.

The economic burden of rheumatoid arthritis in a developing nation: results from a one-year prospective cohort study in Thailand.

Osiri M, Maetzel A, Tugwell P.

J Rheumatol. 2007 Jan;34(1):57-63. Epub 2006 Dec 15.

PMID:
17183621
16.

Primary therapist model for patients referred for rheumatoid arthritis rehabilitation: a cost-effectiveness analysis.

Li LC, Maetzel A, Davis AM, Lineker SC, Bombardier C, Coyte PC.

Arthritis Rheum. 2006 Jun 15;55(3):402-10.

17.
18.

Cost-effectiveness analysis: out of touch with clinical reality?

Maetzel A.

Arthritis Rheum. 2005 Feb 15;53(1):3-4. No abstract available.

20.

[The role of utilities in economic evaluations of healthcare interventions-an introduction].

Maetzel A.

Z Rheumatol. 2004 Oct;63(5):380-4. Review. German.

PMID:
15517298
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk